Plain-English translation of NCT07189169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a major research study testing whether — a traditional herbal medicine formulated as a granule — can help treat intermediate age-related macular degeneration (AMD), a condition that affects the center of your vision as you age. Researchers will compare people taking the medication to those taking a placebo (a fake treatment that looks identical) to see if the real treatment slows vision loss.
Intermediate AMD is a serious condition that can lead to blindness if it progresses, and current treatment options are limited. This study aims to find out whether this medication might be an effective way to slow the disease and help preserve vision in patients who are at risk of further vision decline.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the real medication or a placebo that looks identical — neither you nor the researchers will know which one you're taking. You'll take the medication twice daily as granules mixed with water. You'll need to visit the clinic multiple times for eye exams, vision tests, and imaging of your macula to see whether the treatment is slowing your vision loss.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Smilebiotek Zhuhai Limited
Enrollment target
~400 participants
Started
July 2025
Primary completion
March 2027
Age range
45 Years – 85 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hong Dai
Smilebiotek Zhuhai Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.